The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
Journal of Gastroenterology and Hepatology2021Vol. 36(10), pp. 2952–2959
Citations Over TimeTop 10% of 2021 papers
Susrichit Phrueksotsai, Kanokwan Pinyopornpanish, Juntima Euathrongchit, Apinya Leerapun, Arintaya Phrommintikul, Supawan Buranapin, Nipon Chattipakorn, Satawat Thongsawat
Abstract
Dapagliflozin treatment for 12 weeks is associated with improvement in hepatic fat content, a decrease in visceral fat and bodyweight, enhanced glycemic control, and improved liver biochemistry among T2DM patients with NAFLD.
Related Papers
- → Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus(2011)113 cited
- → Early drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany(2016)4 cited
- [SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].(2013)
- → An update on dapagliflozin for chronic kidney disease(2022)1 cited
- Dapagliflozin: a selective sodium-glucose co-transporter-2 inhibitor in type 2 diabetes.(2011)